Companies Dominating the Diverticulitis Drugs Landscape
- Emmaus Life Sciences, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Synergy Pharma
- Abbott Laboratories
- GlaxoSmithKline plc
- Ardelyx, Inc.
- Gilead Sciences, Inc.
- Trumac Healthcare
- Pfizer Inc.
- Hikma Pharmaceuticals PLC
- Takeda Pharmaceutical Company Limited
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
Diverticulitis Drugs Market size is set to expand at significant growth rate during the forecast period i.e., between 2025-2037.
Growing prevalence of gastrointestinal problems backed by unhealthy diet, lifestyle diseases, and obesity, will propel the market growth.
North America industry is predicted to dominate majority revenue share by 2037, on account of rising obese population, and availability of advanced treatment options.
The major players in the market are Abbott Laboratories, Pfizer Inc., GlaxoSmithKline plc, Ardelyx, Inc., Gilead Sciences, Inc., Trumac Healthcare, Hikma Pharmaceuticals PLC, Takeda Pharmaceutical Company Limited and others.
